Bortezomib-AFT New Zealand - English - Medsafe (Medicines Safety Authority)

bortezomib-aft

aft pharmaceuticals ltd - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib-aft, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib-aft, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib-aft is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Apo-Bortezomib New Zealand - English - Medsafe (Medicines Safety Authority)

apo-bortezomib

apotex nz ltd - bortezomib 3.5mg (as mannitol boronic ester formed during finished product manufacture) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as mannitol boronic ester formed during finished product manufacture) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and have progressive disease.

Bortezomib - Dr. Reddy's New Zealand - English - Medsafe (Medicines Safety Authority)

bortezomib - dr. reddy's

dr reddy's new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib - dr. reddy's, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib - dr. reddy's as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib - dr. reddy's is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Bortezomib B-Medical 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib b-medical 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial

b-medical b.v. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib

Bortezomib Krka 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib krka 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial

krka d.d. novo mesto d.d. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib

Bortezomib Viatris 3.5 mg inj. sol. (pwdr.) s.c./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib viatris 3.5 mg inj. sol. (pwdr.) s.c./i.v. vial

viatris gx bv-srl - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib

Bortezomib Sandoz 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib sandoz 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial

sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib

Bortezomib Teva 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib teva 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial

teva pharma belgium sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib

Bortezomib Sandoz 2,5 mg inj. sol. (pwdr.) i.v./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib sandoz 2,5 mg inj. sol. (pwdr.) i.v./s.c. vial

sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg - powder for solution for injection - 2,5 mg - bortezomib mannitol boronic ester - bortezomib

Bortezomib Waverley Pharma Europe 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bortezomib waverley pharma europe 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial

waverley pharma europe ltd. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib